Names | |
---|---|
Preferred IUPAC name
(1R,2R,3S,3aR,8bS)-1,8b-Dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-2-carboxamide | |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C29H31NO7 | |
Molar mass | 505.567 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Rocaglamide is a natural product which belongs to a class of molecules called flavaglines. [1] [2] This compound was isolated in 1982 by King, Ming-Lu (金明儒) and colleagues based on its antileukemic activity. [3] The name of Rocaglamide is named from two parts: Roc- and aglamide. Roc- means Republic of China (中華民國), the place in which this product isolated; aglamide indicates this product is isolated from Large-leaved Aglaia (Scientific name: Aglaia rimosa [4]). Like other flavaglines, rocaglamide displays potent insecticidal, antifungal, anti-inflammatory and anticancer activities. Rocaglamide A (RocA) inhibits eukaryotic translation initiation by binding to the translation initiation factor eIF4A and converting it into a translational repressor. [5]
Rocaglamide was first synthesized by Barry Trost in 1990. [6] Although other syntheses have been described since, Trost’s remains the only one to afford rocaglamide in an enantio-specific manner.
Names | |
---|---|
Preferred IUPAC name
(1R,2R,3S,3aR,8bS)-1,8b-Dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-N,N-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-2-carboxamide | |
Identifiers | |
3D model (
JSmol)
|
|
ChemSpider | |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C29H31NO7 | |
Molar mass | 505.567 g·mol−1 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Rocaglamide is a natural product which belongs to a class of molecules called flavaglines. [1] [2] This compound was isolated in 1982 by King, Ming-Lu (金明儒) and colleagues based on its antileukemic activity. [3] The name of Rocaglamide is named from two parts: Roc- and aglamide. Roc- means Republic of China (中華民國), the place in which this product isolated; aglamide indicates this product is isolated from Large-leaved Aglaia (Scientific name: Aglaia rimosa [4]). Like other flavaglines, rocaglamide displays potent insecticidal, antifungal, anti-inflammatory and anticancer activities. Rocaglamide A (RocA) inhibits eukaryotic translation initiation by binding to the translation initiation factor eIF4A and converting it into a translational repressor. [5]
Rocaglamide was first synthesized by Barry Trost in 1990. [6] Although other syntheses have been described since, Trost’s remains the only one to afford rocaglamide in an enantio-specific manner.